Literature DB >> 18032745

Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations.

F E Jansen1, O Braams, K L Vincken, A Algra, P Anbeek, A Jennekens-Schinkel, D Halley, B A Zonnenberg, A van den Ouweland, A C van Huffelen, O van Nieuwenhuizen, M Nellist.   

Abstract

OBJECTIVE: The purpose of this study was to systematically analyze the associations between different TSC1 and TSC2 mutations and the neurologic and cognitive phenotype in patients with tuberous sclerosis complex (TSC).
METHODS: Mutation analysis was performed in 58 patients with TSC. Epilepsy variables, including EEG, were classified. A cognition index was determined based on a comprehensive neuropsychological assessment. On three-dimensional fluid-attenuated inversion recovery MR images, an automated tuber segmentation program detected and calculated the number of tubers and the proportion of total brain volume occupied by tubers (tuber/brain proportion [TBP]).
RESULTS: As a group, patients with a TSC2 mutation had earlier age at seizure onset, lower cognition index, more tubers, and a greater TBP than those with a TSC1 mutation, but the ranges overlapped considerably. Familial cases were older at seizure onset and had a higher cognition index than nonfamilial cases. Patients with a mutation deleting or directly inactivating the tuberin GTPase activating protein (GAP) domain had more tubers and a greater TBP than those with an intact GAP domain. Patients with a truncating TSC1 or TSC2 mutation differed from those with nontruncating mutations in seizure types only.
CONCLUSIONS: Although patients with a TSC1 mutation are more likely to have a less severe neurologic and cognitive phenotype than those with a TSC2 mutation, the considerable overlap between both aspects of the phenotype implies that prediction of the neurologic and cognitive phenotypes in individuals with tuberous sclerosis complex should not be based on their particular TSC1 or TSC2 mutation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032745     DOI: 10.1212/01.wnl.0000280578.99900.96

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Resting and task-modulated high-frequency brain rhythms measured by scalp encephalography in infants with tuberous sclerosis complex.

Authors:  Catherine Stamoulis; Vanessa Vogel-Farley; Geneva Degregorio; Shafali S Jeste; Charles A Nelson
Journal:  J Autism Dev Disord       Date:  2015-02

Review 2.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

3.  MRI findings reveal three different types of tubers in patients with tuberous sclerosis complex.

Authors:  Anne Gallagher; Ellen P Grant; Neel Madan; Delma Y Jarrett; David A Lyczkowski; Elizabeth A Thiele
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

4.  Genotype and brain pathology phenotype in children with tuberous sclerosis complex.

Authors:  Iris E Overwater; Rob Swenker; Emma L van der Ende; Kimberley Bm Hanemaayer; Marianne Hoogeveen-Westerveld; Agnies M van Eeghen; Maarten H Lequin; Ans Mw van den Ouweland; Henriëtte A Moll; Mark Nellist; Marie-Claire Y de Wit
Journal:  Eur J Hum Genet       Date:  2016-07-13       Impact factor: 4.246

5.  Genotype and cognitive phenotype of patients with tuberous sclerosis complex.

Authors:  Agnies M van Eeghen; Margaux E Black; Margaret B Pulsifer; David J Kwiatkowski; Elizabeth A Thiele
Journal:  Eur J Hum Genet       Date:  2011-12-21       Impact factor: 4.246

6.  Comparative study of cellular and synaptic abnormalities in brain tissue samples from pediatric tuberous sclerosis complex and cortical dysplasia type II.

Authors:  Carlos Cepeda; Véronique M André; Irene Yamazaki; Jason S Hauptman; Jane Y Chen; Harry V Vinters; Gary W Mathern; Michael S Levine
Journal:  Epilepsia       Date:  2010-07       Impact factor: 5.864

Review 7.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

Review 8.  A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Authors:  David M Feliciano; Tiffany V Lin; Nathaniel W Hartman; Christopher M Bartley; Cathryn Kubera; Lawrence Hsieh; Carlos Lafourcade; Rachel A O'Keefe; Angelique Bordey
Journal:  Int J Dev Neurosci       Date:  2013-02-26       Impact factor: 2.457

Review 9.  Subependymal giant cell astrocytoma: current concepts, management, and future directions.

Authors:  Taohui Ouyang; Na Zhang; Thomas Benjamin; Long Wang; Jiantong Jiao; Yiqing Zhao; Jian Chen
Journal:  Childs Nerv Syst       Date:  2014-02-19       Impact factor: 1.475

10.  Missense mutations to the TSC1 gene cause tuberous sclerosis complex.

Authors:  Mark Nellist; Diana van den Heuvel; Diane Schluep; Carla Exalto; Miriam Goedbloed; Anneke Maat-Kievit; Ton van Essen; Karin van Spaendonck-Zwarts; Floor Jansen; Paula Helderman; Gabriella Bartalini; Outi Vierimaa; Maila Penttinen; Jenneke van den Ende; Ans van den Ouweland; Dicky Halley
Journal:  Eur J Hum Genet       Date:  2008-10-01       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.